Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.43 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | PTGFR | P43088 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27547657 | 0.82 | TAAR1 (0.45) | TAAR1F2RL1PTGS1PTGS2KCNH2 | |
| SCHEMBL409924 | 0.82 | TAAR1 (0.45) | TAAR1MMP2MMP9MMP12MMP13 | |
| SCHEMBL14005420 | 0.80 | TAAR1 (0.54) | TAAR1F2RL1PTGER1PTGFRPTGS1 | |
| SCHEMBL1138928 | 0.80 | TAAR1 (0.43) | TAAR1F2RL1PTGER1PTGFRPTGS1 | |
| SCHEMBL10247192 | 0.80 | CYP1A2 (0.43) | TAAR1PTGFRMMP2MMP9MMP12 | |
| SCHEMBL6692566 | 0.80 | TAAR1 (0.43) | TAAR1F2RL1PTGER1PTGFRPTGS1 | |
| SCHEMBL3769347 | 0.79 | MMP12 (0.49) | MMP2MMP9MMP12MMP13MMP14 | |
| SCHEMBL8371056 | 0.79 | MMP12 (0.49) | MMP2MMP9MMP12MMP13MMP14 | |
| SCHEMBL14327418 | 0.79 | TAAR1 (0.50) | TAAR1F2RL1PTGS1PTGS2MAOB | |
| SCHEMBL12517335 | 0.78 | MMP12 (0.53) | MMP2MMP9MMP12MMP13MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-8513294-B2 | Substituted imidazole derivatives and methods of use thereof for treating cancer | OSTA BIOTECHNOLOGIES (CA) | 2013-08-20 | — | — | US | disclosed |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | disclosed |
| US-7943650-B2 | Methods of treating cancer with imidazolyl compounds | OSTA BIOTECHNOLOGIES (CA) | 2011-05-17 | — | — | US | disclosed |
| EP-2173740-A1 | HEME-OXYGENASE INHIBITORS AND USE OF THE SAME IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM | Osta Biotechnologies (CA) | 2010-04-14 | — | — | EP | disclosed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | disclosed |
| WO-2008151437-A1 | HEME-OXYGENASE INHIBITORS AND USE OF THE SAME IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM | OSTA BIOTECHNOLOGIES (CA) | 2008-12-18 | — | — | WO | disclosed |
| US-20080292547-A1 | Novel Imaging Agents for Fibrosis | TOLLESHAUG HELGE | 2008-11-27 | — | — | US | disclosed |
| US-20080292547-A1 | Novel Imaging Agents for Fibrosis | TOLLESHAUG HELGE | 2008-11-27 | — | — | US | disclosed |
| WO-2007066119-A2 | NOVEL IMAGING AGENTS FOR FIBROSIS | GE HEALTHCARE LIMITED (GB) | 2007-06-14 | — | — | WO | disclosed |
| EP-0005980-B1 | DERIVATIVES OF SUBSTITUTED N-ALKYL IMIDAZOLES, THEIR PREPARATION AND THESE COMPOUNDS FOR PHARMACEUTICAL USE | SYNTEX (U.S.A.) INC. (US) | 1984-08-29 | — | — | EP | disclosed |
| US-4272545-A | FUNGICIDES, BACTERICIDE, ANTIPROTOZOA, SPERMATOCIDE | SYNTEX (U.S.A.) INC. (US) | 1981-06-09 | — | — | US | disclosed |
| US-4213991-A | BACTERICIDES, FUNGICIDES, ANTIPROTOZOA | SYNTEX (U.S.A.) INC. (US) | 1980-07-22 | — | — | US | disclosed |
| EP-0005980-A2 | Derivatives of substituted N-alkyl imidazoles, their preparation and these compounds for pharmaceutical use | SYNTEX (U.S.A.) INC. (US) | 1979-12-12 | — | — | EP | disclosed |
| US-3987087-A | ANTI-ULCER, NASAL PATENCY, WOUND HEALING, LABOR INDUCEMENT | THE UPJOHN COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | TXNRD2, HMOX1, HMOX2 | TAAR1 1059/4885F2RL1 3639/4885PTGER1 664/4885 |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | TAAR1 2422/4885F2RL1 4001/4885PTGER1 527/4885 |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | TAAR1 2422/4885F2RL1 4001/4885PTGER1 527/4885 |
| US-20080292547-A1 | Novel Imaging Agents for Fibrosis | LOXL1, LOXL2, LOXL3 | TAAR1 618/4885F2RL1 105/4885PTGER1 149/4885 |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | TAAR1 2611/4885F2RL1 4014/4885PTGER1 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.